Anthropic Is Entering "This Field" Too? Who Stands to Benefit? [Weekend Money]

Pursuing automation across the entire drug development process
Short-term beneficiaries: CROs conducting validation and experiment-related companies
Mid-term beneficiaries: robotics and hardware companies
"Companies with collaborative research achievements also in focus"

Anthropic, an artificial intelligence (AI) company, said it would enter the biotech and healthcare sectors as part of its initial public offering (IPO), prompting views that a range of companies could benefit.

Shin Jihoon, a researcher at KB Securities, said in a recent report titled "Anthropic's Thinking" that "Anthropic is pursuing automation across the entire drug development process, going beyond simply supplying AI software," adding that "investors should watch how the beneficiaries change across each part of the drug development value chain."

Anthropic recently outlined its strategy for the biotech and healthcare sectors in its IPO registration statement. The strategy involves applying AI across the entire pharmaceutical and biotech research and development process, and, over the longer term, considering the development of its own drugs. To achieve this, the company is also working to build in-house life sciences research capabilities, including by developing specialized AI platforms, acquiring biotech companies, recruiting biotech specialists, and establishing its own molecular biology research lab.

Shin said demand for experiments and validation is likely to increase in the short term. He expects growth in AI-driven candidate compound generation and research hypothesis development to benefit contract research organizations (CROs) that conduct biological validation, preclinical testing service providers, laboratory analysis equipment and related consumables suppliers, and contract manufacturing organizations (CMOs).

In the medium term, as laboratory automation is expected to expand, demand for hardware such as robotics and automated laboratory equipment is likely to grow as AI becomes more closely integrated with laboratory equipment, he said.

This content was produced with the assistance of AI translation services.